Results 11 to 20 of about 1,923,383 (256)

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor, Johannessen, Ingolfur, Talbot, Simon, Cheadle, Eleanor J, Crawford, Dorothy, Gilham, David, Gilham, David E, Johannessen, Ingo, Swanson, Anna   +8 more
core   +1 more source

An Interesting Similarity of Bacillus Calmette-Guerin and Chimeric Antigen Receptor T Cells

Translational Research in Urology, 2020
Intravesical Bacillus Calmette-Guerin (BCG) is approved for non-muscle invasive bladder cancer treatment a long time ago. Chimeric antigen receptor T cells (CAR-Tcell), are T cells are genetically engineered T cells that produce an artificial T-cell ...
Seyed Saeed Tamehri Zadeh, AhmadReza Rezaeian   +1 more
doaj   +1 more source

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

New England Journal of Medicine, 2013
Summary Chimeric antigen receptor–modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute
S. Grupp, M. Kalos, D. Barrett, R. Aplenc, David L. Porter, S. Rheingold, D. Teachey, A. Chew, B. Hauck, J. F. Wright, Michael C. Milone, Bruce L. Levine, Carl H. June   +12 more
semanticscholar   +1 more source

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Journal of Clinical Oncology, 2021
PURPOSE To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy.
B. Santomasso, L. Nastoupil, S. Adkins, C. Lacchetti, B. Schneider, M. Anadkat, M. Atkins, Kelly J. Brassil, J. Caterino, I. Chau, M. Davies, M. Ernstoff, L. Fecher, P. Funchain, I. Jaiyesimi, J. Mammen, J. Naidoo, A. Naing, T. Phillips, Laura D. Porter, C. Reichner, Carole Seigel, J. Song, A. Spira, M. Suarez-Almazor, U. Swami, John A. Thompson, Praveen Vikas, Ying-Hong Wang, J. Weber, Kathryn Bollin, M. Ghosh   +31 more
semanticscholar   +1 more source

Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report

Critical Care Explorations, 2021
BACKGROUND:. Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life ...
Kai Singbartl, MD, MPH, Allison Rosenthal, DO, Jose Leis, MD, PhD, Bhavesh Patel, MD, Ayan Sen, MD, MSc   +4 more
doaj   +1 more source

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Journal of Clinical Oncology, 2022
PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months.
T. Martin, S. Usmani, J. Berdeja, M. Agha, A. Cohen, P. Hari, D. Avigan, A. Deol, M. Htut, A. Lesokhin, N. Munshi, E. O'Donnell, A. Stewart, J. Schecter, J. Goldberg, C. Jackson, Tzu-Min Yeh, A. Banerjee, A. Allred, E. Zudaire, W. Deraedt, Y. Olyslager, Changwei Zhou, L. Pacaud, D. Madduri, A. Jakubowiak, Yi Lin, S. Jagannath   +27 more
semanticscholar   +1 more source

CAR-T cell therapy for hematological malignancies: History, status and promise

Heliyon, 2023
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang, Jianpeng Wang, Shusheng Che, Hai Zhao   +3 more
doaj   +1 more source

Global Manufacturing of CAR T Cell Therapy

Molecular Therapy: Methods & Clinical Development, 2017
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types.
Bruce L. Levine, James Miskin, Keith Wonnacott, Christopher Keir   +3 more
doaj   +1 more source

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

New England Journal of Medicine, 2011
SUMMARY We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell ...
D. Porter, B. Levine, M. Kalos, A. Bagg, C. June   +4 more
semanticscholar   +1 more source

Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells [PDF]

Nature Materials
Lymph nodes are crucial organs of the adaptive immune system, orchestrating T cell priming, activation and tolerance. T cell activity and function are highly regulated by lymph nodes, which have a unique structure harbouring distinct cells that work ...
Jia-Qi Shi, Wei Wu, Dong Chen, Ziyan Liao, Tao Sheng, Yan-Fang Wang, Yuejun Yao, Qing Wu, Feng Liu, Ruyi Zhou, Chaojie Zhu, Xin-Yuan Shen, Zheng-Wei Mao, Yuan Ding, Wei-Lin Wang, G. Dotti, Jie Sun, Xiao Liang, Wei-Jia Fang, Peng Zhao, Hong-Jun Li, Zhen Gu   +21 more
semanticscholar   +2 more sources